Glutamate-sensitive imaging and evaluation of cognitive impairment in multiple sclerosis
Abstract
Cognitive impairment (CI) profoundly impacts quality of life for patients with multiple sclerosis (MS). Dysfunctional regulation of glutamate in gray matter (GM) has been implicated in the pathogenesis of MS by post-mortem pathological studies and in CI by in vivo magnetic resonance spectroscopy, yet GM pathology is subtle and difficult to detect using conventional T1- and T2-weighted magnetic resonance imaging (MRI). There is a need for high-resolution, clinically accessible imaging techniques that probe molecular changes in GM.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 19, 2018
- Source ID
- 10.1177/1352458518799583
Entities
People
- Adrienne N. Dula
- Bailey A. Box
- Bailey D. Lyttle
- Benjamin N. Conrad
- Bennett A. Landman
- Francesca Bagnato
- Kristin P O'Grady
- Lindsey M. Thompson
- Lydia J McKeithan
- Paul Newhouse
- Seth A. Smith
- Siddharama Pawate
Organizations
- National Center for Advancing Translational Sciences
- National Eye Institute
- National Institute of Biomedical Imaging and Bioengineering
- National Institute of Neurological Disorders and Stroke
- National Multiple Sclerosis Society
- United States Army Medical Research and Development Command
- University of Texas at Austin
- Vanderbilt University
- Vanderbilt University Medical Center